back to open calls

UK and Canada biomanufacturing innovations in cell and gene therapies

Opens:
26/10/2020
Closes:
23/12/2020
Sectors:
All
Health & Life Sciences
Project Size:

Summary

Innovate UK has partnered with The National Research Council of Canada (NRC) for this funding opportunity aimed at UK SMEs.

This competition aims to identify UK partners who will bring innovative solutions to support and collaborate with the NRC Challenge Program in Health and Disruptive Technologies for Cell and Gene Therapy.

They are specifically looking for projects in the following 2 areas:

  • Process improvement for adeno-associated virus (AAV) based gene therapy
  • Deploy process analytical technologies to perfusion-enabled lentiviral vector manufacturing

 

Eligibility

Your project must:

  • Have total eligible costs of up to £128,000
  • Start by 1 May 2021
  • Be up to 24 months in duration

 

To lead a project your organisation must be either a:

  • UK registered micro, small or medium sized enterprise (SME)
  • Catapult
  • Charity
  • Not for profit organisation

 

Your project must:

  • Intend to exploit the results from or in the UK and Canada
  • Carry out most of its project work in the UK

 

Academic institutions cannot lead. 

 

Before starting an application or being invited to join a project in the Innovation Funding Service, you must have established a partnership with an appropriate research team at NRC Canada.  If you do not name an NRC research partner, you will not be eligible for funding through this competition.

Scope

The aim of this competition is to support improvements in biomanufacturing for cost effective gene and cell-based therapies.

 

Your project must include teams from the UK and Canada’s National Research Council to develop solutions to address one of these two areas:

  • Process improvement for adeno-associated virus (AAV) based gene therapy
  • Deploy process analytical technologies to perfusion-enabled lentiviral vector manufacturing

 

Process improvement for adeno-associated virus (AAV) based gene therapy

Your proposal must:

  • Demonstrate economical viability by coupling your proposal to more cost-effective downstream processing options than what is currently available
  • Be based on transient transfection, developing improvement of serum free media or processes to increase AAV upstream yields
  • Develop faster in-line, online, at-line or off-line process analytical assays to support process development
  • Develop more cost effective, robust and scalable AAV particle separation methods (preferably chromatography based).

 

Deploy process analytical technologies to perfusion-enabled lentiviral vector (LV) manufacturing

You will have access to the perfusion-enabled high yield LV production process developed at NRC.

 

Your proposal must show how you will develop and deploy complementary in-line monitoring technologies for real time process characterisation using:

  • Capacitance frequency scanning (Aber Instruments)
  • Multi-wavelength fluorometry (NRC technology)
  • Raman spectroscopy including analysis algorithms
Interested in this call? Book a free consultation with our team
Book a Consultation
+44 (0) 1925 506 100
Contact Us
Thank you! We will be in touch shortly.
Oops! Something went wrong while submitting the form.